These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 32499442)
41. Huaier aqueous extract sensitizes cells to rapamycin and cisplatin through activating mTOR signaling. Hu Z; Yang A; Fan H; Wang Y; Zhao Y; Zha X; Zhang H; Tu P J Ethnopharmacol; 2016 Jun; 186():143-150. PubMed ID: 27045863 [TBL] [Abstract][Full Text] [Related]
42. Disrupting the mTOR signaling network as a potential strategy for the enhancement of cancer radiotherapy. Dumont FJ; Bischoff P Curr Cancer Drug Targets; 2012 Oct; 12(8):899-924. PubMed ID: 22831276 [TBL] [Abstract][Full Text] [Related]
43. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway. Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144 [TBL] [Abstract][Full Text] [Related]
44. The expanding role of mTOR in cancer cell growth and proliferation. Cargnello M; Tcherkezian J; Roux PP Mutagenesis; 2015 Mar; 30(2):169-76. PubMed ID: 25688110 [TBL] [Abstract][Full Text] [Related]
45. Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression. Lin XM; Hu L; Gu J; Wang RY; Li L; Tang J; Zhang BH; Yan XZ; Zhu YJ; Hu CL; Zhou WP; Li S; Liu JF; Gonzalez FJ; Wu MC; Wang HY; Chen L Gastroenterology; 2017 Apr; 152(5):1187-1202. PubMed ID: 28065789 [TBL] [Abstract][Full Text] [Related]
47. Wnt Signaling and Drug Resistance in Cancer. Zhong Z; Virshup DM Mol Pharmacol; 2020 Feb; 97(2):72-89. PubMed ID: 31787618 [TBL] [Abstract][Full Text] [Related]
48. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Gerlinger M; Swanton C Br J Cancer; 2010 Oct; 103(8):1139-43. PubMed ID: 20877357 [TBL] [Abstract][Full Text] [Related]
49. Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer. Lin KH; Rutter JC; Xie A; Pardieu B; Winn ET; Bello RD; Forget A; Itzykson R; Ahn YR; Dai Z; Sobhan RT; Anderson GR; Singleton KR; Decker AE; Winter PS; Locasale JW; Crawford L; Puissant A; Wood KC Nat Genet; 2020 Apr; 52(4):408-417. PubMed ID: 32203462 [TBL] [Abstract][Full Text] [Related]
50. The Evolution and Ecology of Resistance in Cancer Therapy. Gatenby RA; Brown JS Cold Spring Harb Perspect Med; 2020 Nov; 10(11):. PubMed ID: 33139405 [TBL] [Abstract][Full Text] [Related]
51. Integrating evolutionary dynamics into cancer therapy. Gatenby RA; Brown JS Nat Rev Clin Oncol; 2020 Nov; 17(11):675-686. PubMed ID: 32699310 [TBL] [Abstract][Full Text] [Related]
52. The conditional nature of gene essentiality. Larrimore KE; Rancati G Curr Opin Genet Dev; 2019 Oct; 58-59():55-61. PubMed ID: 31470233 [TBL] [Abstract][Full Text] [Related]
53. The Evolution and Ecology of Resistance in Cancer Therapy. Gatenby R; Brown J Cold Spring Harb Perspect Med; 2018 Mar; 8(3):. PubMed ID: 28710258 [TBL] [Abstract][Full Text] [Related]